Cibinqo 200 MG Oral Tablet

RxCUI
2591491
RxNorm name
Cibinqo 200 MG Oral Tablet
Display name
Cibinqo 200 MG Oral Tablet
Full name
Cibinqo 200 MG Oral Tablet
Term type
SY
Status
DailyMed mapping
Updated
2026-06-04 23:38:55

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 2 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
CIBINQOABROCITINIBU.S. Pharmaceuticals16c12a56-4550-414b-ac9d-b785b41fea6b2026-07-09Boxed warning, Warnings, Adverse reactionsExact identifier
rxcui: 2591491
CibinqoABROCITINIBPfizer Laboratories Div Pfizer Inc3f6d6fcd-e9f9-42c8-bfa2-bb2cfc9ed2582026-07-07Boxed warning, Warnings, Adverse reactionsExact identifier
rxcui: 2591491

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 2 matching rows.

Set ID, RxNorm mappings, Terms table
Set IDRxNorm mappingsTermsSPL versionLabelEffective
3f6d6fcd-e9f9-42c8-bfa2-bb2cfc9ed258Cibinqo 200 MG Oral Tablet [PSN] · abrocitinib 200 MG Oral Tablet [Cibinqo] [SBD] · Cibinqo 200 MG Oral Tablet [SY]36These highlights do not include all the information needed to use CIBINQO safely and effectively. See full prescribing information for CIBINQO. CIBINQO ® (abrocitinib) tablets, for oral use Initial U.S. Approval: 202220250109
16c12a56-4550-414b-ac9d-b785b41fea6bCibinqo 200 MG Oral Tablet [PSN] · abrocitinib 200 MG Oral Tablet [Cibinqo] [SBD] · Cibinqo 200 MG Oral Tablet [SY]34These highlights do not include all the information needed to use CIBINQO safely and effectively. See full prescribing information for CIBINQO. CIBINQO ® (abrocitinib) tablets, for oral use Initial U.S. Approval: 202220250320